ARROWHEAD PHARMACEUTICALS, INC.

Sector revisions Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 20:53:07 23/01/2026 GMT			5-day change	1st Jan Change
67.49 ^USD	-3.02%		+5.76%	+1.69%

01-22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
01-13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	ARROWHEAD PHARMACEUTICALS, INC.							12
	ARGENX SE							15
	WUXI APPTEC CO., LTD.							18
	INSMED INCORPORATED							19
	BIONTECH SE							19
	WUXI BIOLOGICS (CAYMAN) INC.							25
	GENMAB A/S							13
	AKESO, INC.							22
	SUMMIT THERAPEUTICS INC.							13
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.							17
	EXELIXIS, INC.							18
	MADRIGAL PHARMACEUTICALS, INC.							14
	SAMSUNG EPIS HOLDINGS CO., LTD.		-	-	-	-	-	1
	NUVALENT, INC.							17
	CYTOKINETICS, INCORPORATED							18
	REMEGEN CO., LTD.							15
	Average							16
	Weighted average by Cap.							17

Bio Therapeutic Drugs

As early as today, start finding the best investment opportunities!